European Journal of Clinical Pharmacology

, Volume 36, Issue 3, pp 319–321 | Cite as

The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers

  • P. A. Philip
  • C. A. James
  • H. J. Rogers
Short Communications

Summary

We have studied the effect of cimetidine (800 mg·day−1) administration for three days on debrisoquine 4-hydroxylation in nine healthy extensive metabolizers.

The debrisoquine metabolic ratio was significantly increased (p<0.01), but the new ratios remained in the extensive metabolizer range (<12.6).

These data suggest that pre-treatment with cimetidine in usual therapeutic doses will impair debrisoquine 4-hydroxylation, but not enough to alter the apparent oxidation phenotype.

Key words

cimetidine debrisoquine drug interactions extensive metabolizers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amsterdam JD, Brunswick DJ, Potter L, Kaplan MJ (1984) Cimetidine-induced alterations in desipramine plasma concentrations. Psychopharmacology 83: 373–375Google Scholar
  2. Bertilsson L, Aberg-Wistedt A (1983) The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 15: 388–389Google Scholar
  3. Clark DWG (1985) Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 29: 342–375Google Scholar
  4. Eichelbaum M (1982) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokinet 7: 1–22Google Scholar
  5. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105Google Scholar
  6. Feely J, Wilkinson GR, Wood AJJ (1981) Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304: 692–695Google Scholar
  7. Henauer SA, Hollister LE (1984) Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther 35: 183–187Google Scholar
  8. Lennard MS, Silas JH, Smith AJ, Tucker GT (1977) Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 133: 161–166Google Scholar
  9. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586Google Scholar
  10. Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL (1983) Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol 15: 443–450Google Scholar
  11. Somogyi A, Muirhead M (1987) Pharmacokinetic interactions of cimetidine. Clin Pharmacokinet 12: 321–366Google Scholar
  12. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F (1987) Reduction of metformin renal excretion by cimetidine in man. Br J Clin Pharmacol 23: 545–551Google Scholar
  13. Steiner E, Iselius L, Alvan G, Lindsten J, Sjöqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin Pharmacol Ther 38: 394–401Google Scholar
  14. Von-Bahr C, Birgersson C, Morgan ET, Eriksson O, Goransson M, Spina E, Woodhouse K (1986) Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations. Xenobiotica 16: 391–400Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • P. A. Philip
    • 1
    • 2
  • C. A. James
    • 1
  • H. J. Rogers
    • 1
  1. 1.Department of Clinical PharmacologyUnited Medical and Dental Schools, Guy's HospitalLondonUK
  2. 2.ICRF Clinical Oncology Unit Churchill HospitalHeadingtonUK

Personalised recommendations